全文获取类型
收费全文 | 376574篇 |
免费 | 24928篇 |
国内免费 | 2789篇 |
专业分类
耳鼻咽喉 | 5183篇 |
儿科学 | 8182篇 |
妇产科学 | 10075篇 |
基础医学 | 52827篇 |
口腔科学 | 11767篇 |
临床医学 | 29911篇 |
内科学 | 77846篇 |
皮肤病学 | 8540篇 |
神经病学 | 27036篇 |
特种医学 | 13899篇 |
外国民族医学 | 82篇 |
外科学 | 60427篇 |
综合类 | 9928篇 |
现状与发展 | 1篇 |
一般理论 | 64篇 |
预防医学 | 17294篇 |
眼科学 | 9413篇 |
药学 | 30896篇 |
1篇 | |
中国医学 | 2169篇 |
肿瘤学 | 28750篇 |
出版年
2021年 | 2364篇 |
2019年 | 2717篇 |
2018年 | 4512篇 |
2017年 | 3427篇 |
2016年 | 3515篇 |
2015年 | 4014篇 |
2014年 | 5687篇 |
2013年 | 7367篇 |
2012年 | 10002篇 |
2011年 | 10182篇 |
2010年 | 6173篇 |
2009年 | 5834篇 |
2008年 | 9435篇 |
2007年 | 10268篇 |
2006年 | 10192篇 |
2005年 | 9254篇 |
2004年 | 8762篇 |
2003年 | 8486篇 |
2002年 | 8160篇 |
2001年 | 28254篇 |
2000年 | 28759篇 |
1999年 | 23608篇 |
1998年 | 5023篇 |
1997年 | 4100篇 |
1996年 | 3679篇 |
1995年 | 3470篇 |
1994年 | 3099篇 |
1993年 | 2837篇 |
1992年 | 16035篇 |
1991年 | 14809篇 |
1990年 | 14152篇 |
1989年 | 13954篇 |
1988年 | 12578篇 |
1987年 | 12056篇 |
1986年 | 11097篇 |
1985年 | 10318篇 |
1984年 | 6908篇 |
1983年 | 5598篇 |
1982年 | 2716篇 |
1979年 | 5476篇 |
1978年 | 3345篇 |
1977年 | 2963篇 |
1975年 | 2636篇 |
1974年 | 3064篇 |
1973年 | 2863篇 |
1972年 | 2828篇 |
1971年 | 2773篇 |
1970年 | 2509篇 |
1969年 | 2543篇 |
1968年 | 2250篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
目的:以灰毡毛忍冬为材料,克隆对-香豆酸3-羟化酶(LmC3H1)基因,进行生物信息学和表达模式分析,结合绿原酸含量,研究推测灰毡毛忍冬LmC3H1基因的功能。方法:通过逆转录聚合酶链式反应(RT-PCR)和RACE技术克隆LmC3H1基因的全长c DNA序列,对该序列进行生物信息学分析,并利用实时荧光定量PCR(Real-time PCR)和HPLC分别测定灰毡毛忍冬茎、叶及不同花期花中LmC3H1的相对表达量及绿原酸含量。结果:克隆得LmC3H1(Gen Bank:MN177695)基因,开放阅读框(ORF)长度为1 533 bp,编码510个氨基酸,推测其分子式为C_(2618)H_(4134)N_(718)O_(727)S_(22),相对分子质量为58 005.32,等电点8.92,为亲水性蛋白,定位于叶绿体中,具有跨膜区域LLLIPAVLFLISLVYPLI,含有细胞色素P450的保守结构域CYTOCHROME_P450(422-433 aa);Real-time PCR结果显示,LmC3H1在灰毡毛忍冬茎、叶及不同花期花有不同程度的表达,其中在花发育阶段,白色花蕾期相对表达量最高,花蕾初期及白色开花期次之;白色花蕾期花与茎、叶比,花的相对表达量最高,叶的最低;HPLC结果显示,从绿白色花蕾期到金黄色开花期绿原酸含量呈上升趋势,金黄色开花期含量最高,不同器官中,花中绿原酸最高,茎最低。结论:克隆得到灰毡毛忍冬LmC3H1基因,推测LmC3H1可能参与灰毡毛忍冬花绿原酸的生物合成。该研究为进一步研究该基因的功能及探究灰毡毛忍冬绿原酸生物合成和调节机制提供了依据,同时为遗传改良灰毡毛忍冬品质奠定了基础。 相似文献
73.
74.
75.
76.
77.
78.
Harsh Goel Joshua Melot Matthew D. Krinock Ashish Kumar Sunil K. Nadar Gregory Y. H. Lip 《Annals of medicine》2020,52(8):444-461
Abstract Cardiac troponins (cTn) are currently the standard of care for the diagnosis of acute coronary syndromes (ACS) in patients presenting to the emergency department (ED) with chest pain (CP). However, their plasma kinetics necessitate a prolonged ED stay or overnight hospital admission, especially in those presenting early after CP onset. Moreover, ruling out ACS in low-risk patients requires prolonged ED observation or overnight hospital admission to allow serial measurements of c-Tn, adding cost. Heart-type fatty acid-binding protein (H-FABP) is a novel marker of myocardial injury with putative advantages over cTn. Being present in abundance in the myocellular cytoplasm, it is released rapidly (<1?h) after the onset of myocardial injury and could potentially play an important role in both earlier diagnosis of high-risk patients presenting early after CP onset, as well as in risk-stratifying low-risk patients rapidly. Like cTn, H-FABP also has a potential role as a prognostic marker in other conditions where the myocardial injury occurs, such as acute congestive heart failure (CHF) and acute pulmonary embolism (PE). This review provides an overview of the evidence examining the role of H-FABP in early diagnosis and risk stratification of patients with CP and in non-ACS conditions associated with myocardial injury.
- Key messages
-
Heart-type fatty acid-binding protein is a biomarker that is elevated early in myocardial injury
-
The routine use in the emergency department complements the use of troponins in ruling out acute coronary syndromes in patients presenting early with chest pain
-
It also is useful in risk stratifying patients with other conditions such as heart failure and acute pulmonary embolism.
79.
Alicia León-Castillo Ester Gilvazquez Remi Nout Vincent THBM Smit Jessica N McAlpine Melissa McConechy Stefan Kommoss Sara Y Brucker Joseph W Carlson Elisabeth Epstein Tilman T Rau Robert A Soslow Raji Ganesan Xavier Matias-Guiu Esther Oliva Beth T Harrison David N Church C Blake Gilks Tjalling Bosse 《The Journal of pathology》2020,250(3):312-322
Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer Genome Atlas (TCGA) has gained relevance in recent years due to its prognostic utility and potential to predict benefit from adjuvant treatment. While most ECs can be classified based on a single classifier (POLE exonuclease domain mutations – POLEmut, MMR deficiency – MMRd, p53 abnormal – p53abn), a small but clinically relevant group of tumours harbour more than one molecular classifying feature and are referred to as ‘multiple-classifier’ ECs. We aimed to describe the clinicopathological and molecular features of multiple-classifier ECs with abnormal p53 (p53abn). Within a cohort of 3518 molecularly profiled ECs, 107 (3%) tumours displayed p53abn in addition to another classifier(s), including 64 with MMRd (MMRd–p53abn), 31 with POLEmut (POLEmut–p53abn), and 12 with all three aberrations (MMRd–POLEmut–p53abn). MMRd–p53abn ECs and POLEmut–p53abn ECs were mostly grade 3 endometrioid ECs, early stage, and frequently showed morphological features characteristic of MMRd or POLEmut ECs. 18/28 (60%) MMRd–p53abn ECs and 7/15 (46.7%) POLEmut–p53abn ECs showed subclonal p53 overexpression, suggesting that TP53 mutation was a secondary event acquired during tumour progression. Hierarchical clustering of TCGA ECs by single nucleotide variant (SNV) type and somatic copy number alterations (SCNAs) revealed that MMRd–p53abn tumours mostly clustered with single-classifier MMRd tumours (20/23) rather than single-classifier p53abn tumours (3/23), while POLEmut–p53abn tumours mostly clustered with single-classifier POLEmut tumours (12/13) and seldom with single-classifier p53abn tumours (1/13) (both p ≤ 0.001, chi-squared test). Finally, the clinical outcome of patients with MMRd–p53abn and POLEmut–p53abn ECs [stage I 5-year recurrence-free survival (RFS) of 92.2% and 94.1%, respectively] was significantly different from single-classifier p53abn EC (stage I RFS 70.8%, p = 0.024 and p = 0.050, respectively). Our results support the classification of MMRd–p53abn EC as MMRd and POLEmut–p53abn EC as POLEmut. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. 相似文献